Peptide Atlas · Peptide

Goserelin

Goserelin is a GnRH agonist analogue that reduces testosterone secretion; in a randomized trial in 415 men with locally advanced prostate cancer, adding three years of goserelin to radiotherapy raised five-year survival from 62% to 79%.

established

provisional
PubChem 5311128
2 citations
0 discussions
0 followers
D-Ser(tBu)6-AzaGly10-LHRH
Goserelin acetate
Zoladex

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Goserelin. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Goserelin during chemotherapy reduced ovarian failure in breast cancer (POEMS RCT)	established	pmid 25738668
Radiotherapy plus goserelin improved survival in locally advanced prostate cancer (RCT)	established	pmid 9233866

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.